Washington, Nov 18 (UNI) The final analysis of the Phase III clinical trials of Pfizer's coronavirus vaccine has shown 95 percent efficiency, announced the company on Wednesday.

Pfizer which has developed the vaccine in cooperation with German biotechnology company BioNTech had in an earlier statement claimed the vaccine to be 90 percent effective.

Pfizer said in a press release

"Analysis of the data indicates a vaccine efficacy rate of 95% (p< 0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics,."

The efficacy in adults aged over 65 is estimated at over 94 percent, the press release claimed.

"There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group," Pfizer added.

UNI XC-GNK RKM